Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 12,905 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 12,905 shares of Kymera Therapeutics stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $79.36, for a total transaction of $1,024,140.80. Following the transaction, the chief operating officer owned 48,297 shares of the company’s stock, valued at approximately $3,832,849.92. The trade was a 21.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $81.70 on Thursday. The firm has a 50 day simple moving average of $83.28 and a 200-day simple moving average of $79.14. The firm has a market cap of $6.72 billion, a PE ratio of -22.89 and a beta of 2.06. Kymera Therapeutics, Inc. has a 1-year low of $28.33 and a 1-year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company’s revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.82) earnings per share. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC grew its stake in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares during the period. Larson Financial Group LLC grew its stake in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after buying an additional 349 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Kymera Therapeutics during the fourth quarter worth approximately $63,000. Bessemer Group Inc. grew its stake in Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares during the period. Finally, Osaic Holdings Inc. grew its stake in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the period.

Analyst Ratings Changes

KYMR has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. BTIG Research lowered their target price on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Morgan Stanley restated an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a report on Thursday, April 30th. Stephens boosted their target price on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. Finally, Canaccord Genuity Group initiated coverage on shares of Kymera Therapeutics in a report on Wednesday, May 6th. They issued a “buy” rating and a $106.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $118.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.